A comparative study of recombinant and native frutalin binding to human prostate tissues
Carla Oliveira1, José A Teixeira, Fernando Schmitt
1Institute for Biotechnology and Bioengineering, Centre of Biological Engineering, Universidade do Minho, Campus de Gualtar, 4710-057 Braga, Portugal. carlaoliveira@deb.uminho.pt
BMC Biotechnology
|September 11, 2009
Summary
This study investigated the use of frutalin lectins for prostate cancer detection. Recombinant frutalin showed significant potential as a prostate cancer biomarker, binding specifically to malignant cells.
Area of Science:
- Biochemistry
- Oncology
- Histochemistry
Background:
- Cancer cells exhibit altered glycosylation patterns detectable by lectin histochemistry.
- Prostate carcinoma, a lethal cancer, shows specific glycosylation changes.
- Frutalin, an alpha-D-galactose-binding lectin, was explored for detecting these changes.
Purpose of the Study:
- To investigate the potential of plant-derived (native) and recombinant frutalin as biomarkers for prostate carcinoma.
- To compare the diagnostic utility of native and recombinant frutalin in prostate cancer detection.
Main Methods:
- Immunohistochemical techniques were employed to assess lectin binding to human prostate tissues.
- Both native and recombinant frutalin were tested on 20 prostate carcinoma and 25 benign prostate hyperplasia samples.
- DAB staining visualized lectin binding localization within tissue samples.
Main Results:
- Both native and recombinant frutalin bound to prostate carcinoma cells.
- Native frutalin showed stronger binding in neoplastic cells than hyperplastic cells, but lacked statistical significance (P=0.051).
- Recombinant frutalin demonstrated exclusive and statistically significant binding to neoplastic cells (P<0.00001), though not in all cases and with heterogeneous intensity.
Conclusions:
- Native and recombinant frutalin exhibit differential binding in prostate tissues due to varying affinities.
- Both frutalin forms show promise as histochemical biomarkers for prostate cancer.
- The study successfully demonstrated the use of recombinant lectins in prostate cancer immunohistochemistry, highlighting advantages for diagnostic purity.
